Blood Res 2022; 57(1):
Published online March 31, 2022
https://doi.org/10.5045/br.2022.2022043
© The Korean Society of Hematology
Correspondence to : Jun Ho Jang, M.D., Ph.D.
Yeung-Chul Mun, M.D., Ph.D.
Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul 06351, Korea (J.H.J.)
Division of Hematology-Oncology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, 1071, Anyangcheon-ro, Yangcheon-gu, Seoul 07985, Korea (Y.C.M.)
E-mail: J.H.J., smcjunhojang@gmail.com
Y.C.M., yeungchul@ewha.ac.kr
#These authors contributed equally to this work.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Despite the availability of therapies to treat patients with immune thrombocytopenia (ITP), there is currently little data from randomized trials to assist clinicians in managing patients. The evidence-based guidelines of the Korean Society of Hematology Aplastic Anemia Working Party (KSHAAWP) are intended to support patients and physicians in the management of ITP. Experts from the KSHAAWP discussed and described this guideline according to the current treatment situation for ITP in Korea and finalized the guidelines. The expert panel recommended the management of ITP in adult and pediatric patients with newly diagnosed, persistent, and chronic disease refractory to first-line therapy with minor bleeding. Management approaches include observation and administration of corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, and thrombopoietin receptor agonists. Currently, evidence supporting strong recommendations for various management approaches is lacking. Therefore, a large focus was placed on shared decision-making, especially regarding second-line treatment.
Keywords Immune thrombocytopenia, Recommendation, Management
Blood Res 2022; 57(1): 20-28
Published online March 31, 2022 https://doi.org/10.5045/br.2022.2022043
Copyright © The Korean Society of Hematology.
Young Hoon Park1#, Dae-Young Kim2#, Seongkoo Kim3, Young Bae Choi4, Dong-Yeop Shin5, Jin Seok Kim6, Won Sik Lee7, Yeung-Chul Mun1, Jun Ho Jang8, Jong Wook Lee9, Hoon Kook10, on behalf of Korean Aplastic Anemia Working Party
1Division of Hematology-Oncology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, 2Department of Internal Medicine, Uijeongbu Eulji Medical Center, Eulji Univerisity, 3Department of Pediatrics, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, 4Department of Pediatrics, Ajou University School of Medicine, Ajou Univeristy Hospital, Suwon, 5Department of Internal Medicine, Seoul National University Hospital, 6Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, 7Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, 8Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 9Department of Hematology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, 10Department of Pediatrics, Chonnam National University Hwasun Hospital, Hwasun, Korea
Correspondence to:Jun Ho Jang, M.D., Ph.D.
Yeung-Chul Mun, M.D., Ph.D.
Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul 06351, Korea (J.H.J.)
Division of Hematology-Oncology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, 1071, Anyangcheon-ro, Yangcheon-gu, Seoul 07985, Korea (Y.C.M.)
E-mail: J.H.J., smcjunhojang@gmail.com
Y.C.M., yeungchul@ewha.ac.kr
#These authors contributed equally to this work.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Despite the availability of therapies to treat patients with immune thrombocytopenia (ITP), there is currently little data from randomized trials to assist clinicians in managing patients. The evidence-based guidelines of the Korean Society of Hematology Aplastic Anemia Working Party (KSHAAWP) are intended to support patients and physicians in the management of ITP. Experts from the KSHAAWP discussed and described this guideline according to the current treatment situation for ITP in Korea and finalized the guidelines. The expert panel recommended the management of ITP in adult and pediatric patients with newly diagnosed, persistent, and chronic disease refractory to first-line therapy with minor bleeding. Management approaches include observation and administration of corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, and thrombopoietin receptor agonists. Currently, evidence supporting strong recommendations for various management approaches is lacking. Therefore, a large focus was placed on shared decision-making, especially regarding second-line treatment.
Keywords: Immune thrombocytopenia, Recommendation, Management
Jun Ho Jang, Ji Yoon Kim, Yeung-Chul Mun, Soo-Mee Bang, Yeon Jung Lim, Dong-Yeop Shin, Young Bae Choi, Ho-Young Yhim, Jong Wook Lee, Hoon Kook, and on the behalf of Korean Aplastic Anemia Working Party
Blood Res 2017; 52(4): 254-263Doaa Mohamed El Demerdash, Maha Mohamed Saber, Alia Ayad, Kareeman Gomaa and Mohamed Abdelkader Morad
Blood Res 2024; 59():Dae Sik Kim
Blood Res 2022; 57(S1): S112-S119